Anthera Announces FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. RIVN
4. VRTX
5. WMT
6. RXST
7. SPGI
8. AGIO
9. WULF
10. CBOE

Go back to Anthera Announces FDA Orphan Drug Designation for Blisibimod for the Treatment of IgA Nephropathy

Anthera Pharma (ANTH) PT Lowered to $1.75 at Jefferies Following 2Q

August 11, 2017 8:08 AM EDT

Jefferies lowered its price target on Anthera Pharma (NASDAQ: ANTH) to $1.75 (from $2.25) while maintaining a Hold rating following the company's 2Q. ANTH reported EPS of $0.03 due to a non-cash gain on fair value of warrants. Operating expenses were $8.7M vs. $11.5M... More